SCHEMBL8013258

SCHEMBL8013258

[CH2]c1ccc(N(Cc2ccccc2)c2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.51
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
KCNA3 P22001 1/20 0.45
TSHR P16473 2/20 0.44
CYP2C19 P33261 1/20 0.42
ALDH1A1 P00352 3/20 0.41
CNR2 P34972 1/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
KCNH2 Q12809 2/20 0.39
AOC3 Q16853 1/20 0.39
NPC1 O15118 1/20 0.38
GLA P06280 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
PAX8 Q06710 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9446230 0.89 NR3C2 (0.59) NR3C2HDAC1HDAC8HDAC6KCNA3
Ethylene SCHEMBL11428459 0.87 NR3C2 (0.53) NR3C2HDAC1HDAC8HDAC6KCNA3
SCHEMBL918512 0.87 NR3C2 (0.56) NR3C2HDAC1HDAC8HDAC6KCNA3
Bromide SCHEMBL4613403 0.84 NR3C2 (0.55) NR3C2HDAC1HDAC8HDAC6KCNA3
SCHEMBL1702260 0.83 NR3C2 (0.54) NR3C2HDAC1HDAC8HDAC6KCNA3
SCHEMBL9215401 0.82 HDAC1 (0.60) NR3C2HDAC1HDAC8HDAC6KCNA3
SCHEMBL2058979 0.81 CYP2C19 (0.64) TSHRCYP2C19ALDH1A1CNR2KCNH2
SCHEMBL9446253 0.79 NR3C2 (0.51) NR3C2HDAC1HDAC8HDAC6KCNA3
SCHEMBL5841663 0.79 MAPT (0.56) NR3C2HDAC1HDAC8HDAC6KCNA3
SCHEMBL9446233 0.79 NR3C2 (0.51) NR3C2HDAC1HDAC8HDAC6KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1066729-C Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-06-06 CN disclosed
US-6117893-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 2000-09-12 US disclosed
US-5977365-A HYPOGLYCEMIC AGENTS SANKYO COMPANY, LIMITED (JP) 1999-11-02 US disclosed
US-5962470-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 1999-10-05 US disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
US-5834501-A TREATING DIABETES OR HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1998-11-10 US disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 US disclosed
CN-1157288-A Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1997-08-20 CN disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 US disclosed
CN-1118781-A Heterocyclic compound with activity against diabetes and preparation and application of same MITSUTAKA CO LTD (JP) 1996-03-20 CN disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed